Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Key insights from lung cancer research at ASCO 2025

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Key insights from lung cancer research at ASCO 2025 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

Cost comparison of IV vs subcutaneous trastuzumab in HER2+ breast cancer in...

Dr Kunvar Harsh Upveja - Biocon Biologics, Bengaluru, India

Cost comparison of IV vs subcutaneous trastuzumab in HER2+ breast cancer in Morocco ( Dr Kunvar Harsh Upveja - Biocon Biologics, Bengaluru, India )

Encorafenib/binimetinib/nivolumab combo improves PFS in BRAF-mutant melanoma...

Dr Zeynep Eroglu - Moffitt Cancer Center, Tampa, USA

Encorafenib/binimetinib/nivolumab combo improves PFS in BRAF-mutant melanoma brain metastases ( Dr Zeynep Eroglu - Moffitt Cancer Center, Tampa, USA )

Enhanced pathologic response with neoadjuvant pembrolizumab plus vidutolimod in...

Dr Ahmad Tarhini - Moffitt Cancer Center, Tampa, USA

Enhanced pathologic response with neoadjuvant pembrolizumab plus vidutolimod in high-risk resectable melanoma ( Dr Ahmad Tarhini - Moffitt Cancer Center, Tampa, USA )

ASCO 2025: Importance of early testing in metastatic prostate cancer

Prof Eleni Efstathiou, Dr Elena Castro, Prof Gerhardt Attard and Dr Brigida...

ASCO 2025: Importance of early testing in metastatic prostate cancer ( Prof Eleni Efstathiou, Dr Elena Castro, Prof Gerhardt Attard and Dr Brigida Maiorano )

Tumour microenvironment and circulating biomarkers predict response to...

Dr David Braun - Yale School of Medicine, New Haven, USA

Tumour microenvironment and circulating biomarkers predict response to immunotherapy in advanced RCC ( Dr David Braun - Yale School of Medicine, New Haven, USA )

ASCO 2025: Latest updates in mRCC

Dr Michael Serzan, Dr Guillermo De Velasco, Dr Alessandro Rametta and Dr Javier...

ASCO 2025: Latest updates in mRCC ( Dr Michael Serzan, Dr Guillermo De Velasco, Dr Alessandro Rametta and Dr Javier Puente )

Upfront modified FOLFOXIRI plus panitumumab improves OS in RAS/BRAF wild-type...

Dr Veronica Conca - University of Pisa, Pisa, Italy

Upfront modified FOLFOXIRI plus panitumumab improves OS in RAS/BRAF wild-type mCRC ( Dr Veronica Conca - University of Pisa, Pisa, Italy )

Nivolumab plus ipilimumab vs gemcitabine-carboplatin in cisplatin-ineligible...

Dr Michiel Simon van der Heijden - Netherlands Cancer Institute, Amsterdam...

Nivolumab plus ipilimumab vs gemcitabine-carboplatin in cisplatin-ineligible metastatic urothelial carcinoma ( Dr Michiel Simon van der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands )

QoL maintained with sasanlimab plus BCG in high-risk, BCG-naive NMIBC

Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany

QoL maintained with sasanlimab plus BCG in high-risk, BCG-naive NMIBC ( Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany )

Long-term infusion of dinutuximab beta improves survival in high-risk...

Dr Ruth Ladenstein - St. Anna Children's Hospital, Vienna, Austria

Long-term infusion of dinutuximab beta improves survival in high-risk neuroblastoma ( Dr Ruth Ladenstein - St. Anna Children's Hospital, Vienna, Austria )

Trastuzumab deruxtecan plus pertuzumab may delay cancer growth for some HER2...

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA

Trastuzumab deruxtecan plus pertuzumab may delay cancer growth for some HER2-positive advanced breast cancers ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer